A5071974181- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Viral-associated cancers and disorders
- Protein Degradation and Inhibitors
- Cardiomyopathy and Myosin Studies
- Hematological disorders and diagnostics
- School Leadership and Teacher Performance
- Neutropenia and Cancer Infections
- Connective tissue disorders research
- Neurogenetic and Muscular Disorders Research
- Sepsis Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Heart Failure Treatment and Management
- Transplantation: Methods and Outcomes
- CNS Lymphoma Diagnosis and Treatment
- Resilience and Mental Health
- Mycobacterium research and diagnosis
- Lung Cancer Treatments and Mutations
- Acute Myeloid Leukemia Research
Klinička bolnica Merkur
2019-2025
Carfilzomib-based regimens brought a significant improvement in the treatment of relapsed/refractory multiple myeloma (RRMM). Even though efficacy and safety profiles carfilzomib are well-established several clinical trials, there is limited real-world data with carfilzomib-based protocols. Here we present our experience for patients RRMM Croatia. Data on starting protocols period between June 2019 February 2023 was collected by retrospective chart review from 14 Croatian centres. A total...
Background/Objectives: In hematological patients receiving treatment for lymphomas, febrile neutropenia (FN) is a serious complication associated with significant morbidity and mortality. This prospective study aimed to evaluate the diagnostic prognostic value of novel biomarker presepsin (PSP) in episodes FN this specific cohort patients. Methods: The enrolled 37 18 without fever as control group. Patients were divided into two groups: those confirmed infections them. Various clinical...
: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy clinical trials for relapsed/refractory multiple myeloma (RRMM).
Background/Objectives: Obinutuzumab was approved for front-line treatment of chronic lymphocytic leukemia in combination with chlorambucil pulses administered every 2 wks. Alternative schedules enable the administration higher total doses, and have better antileukemia activity. So far, evidence on feasibility combining obinutuzumab alternative is lacking. We performed this retrospective analysis to analyze real life outcomes patients receiving a different schedules. Methods: This survey...
To compare the outcomes of Croatian patients with mantle cell lymphoma (MCL) who started treatment in 2007 and 2008 (historical cohort) those between 2015 2017 (recent cohort).The historical cohort consisted 40 rituximab 2008. Data on recent cohort, consisting 89 patients, were collected retrospectively from electronic databases hospitals hematology units. Demographic characteristics data induction regimens, autologous stem transplantation (ASCT), maintenance first remission, event-free...
Background: Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK). Recently, ibrutinib has become available in Croatia for chronic lymphocytic leukemia (CLL) with del17p aberration or early relapse and relapsed/refractory mantle cell lymphoma (MCL) pretreated bendamustine rituximab. BTK inhibition can lead to immunosuppression through B‐ T‐cell resulting increase infections. In literature, systematic meta‐analyses have shown higher incidence infections B‐cell malignancies...
Introduction: Myelodysplastic syndrome (MDS) is one of the most common myeloid neoplasms elderly characterized by cytopenias and limited therapeutic options. The main aim this retrospective single-center study was to examine value classical prognostic factors. outcome overall survival (OS) defined as death from MDS or any other reason. Methods: We analyzed medical records patients diagnosed with at single centre in period beginning 2013 end 2016. Results: Total 58 (median age diagnosis being...